Banque Cantonale Vaudoise Has $56,000 Stock Position in PetIQ, Inc. (NASDAQ:PETQ)

Banque Cantonale Vaudoise lowered its stake in shares of PetIQ, Inc. (NASDAQ:PETQ) by 37.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,546 shares of the company’s stock after selling 1,548 shares during the period. Banque Cantonale Vaudoise’s holdings in PetIQ were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in PETQ. CWM LLC raised its holdings in shares of PetIQ by 86.2% during the second quarter. CWM LLC now owns 1,251 shares of the company’s stock valued at $28,000 after purchasing an additional 579 shares during the period. ICA Group Wealth Management LLC acquired a new position in shares of PetIQ during the fourth quarter valued at about $35,000. First Horizon Advisors Inc. acquired a new position in shares of PetIQ during the second quarter valued at about $36,000. FinTrust Capital Advisors LLC raised its holdings in shares of PetIQ by 50.2% during the first quarter. FinTrust Capital Advisors LLC now owns 2,618 shares of the company’s stock valued at $48,000 after purchasing an additional 875 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of PetIQ by 107.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 5,221 shares of the company’s stock valued at $91,000 after purchasing an additional 2,704 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

Insider Buying and Selling at PetIQ

In other PetIQ news, Director Scott Huff sold 12,117 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $22.19, for a total value of $268,876.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PETQ. William Blair lowered shares of PetIQ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of PetIQ in a report on Friday, May 10th. Finally, Truist Financial lowered shares of PetIQ from a “buy” rating to a “hold” rating and upped their target price for the stock from $30.00 to $31.00 in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.25.

PetIQ Trading Down 0.1 %

PETQ opened at $30.53 on Wednesday. The company has a debt-to-equity ratio of 1.68, a current ratio of 2.58 and a quick ratio of 1.68. The firm has a market capitalization of $912.54 million, a PE ratio of 138.78 and a beta of 1.71. PetIQ, Inc. has a fifty-two week low of $15.09 and a fifty-two week high of $30.68. The company’s 50-day moving average is $25.32 and its 200 day moving average is $20.92.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.50 by $0.20. The firm had revenue of $328.90 million during the quarter, compared to analyst estimates of $330.14 million. PetIQ had a net margin of 1.20% and a return on equity of 18.75%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. As a group, research analysts predict that PetIQ, Inc. will post 1.12 earnings per share for the current fiscal year.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.